Lilly's GLP-1 Surge Dwarfs Abbott's Steady Device Growth With 54% Revenue Jump

Abbott Laboratories (NYSE: ABT) and Eli Lilly (NYSE: LLY) just reported Q3 earnings that highlight two fundamentally different healthcare bets. Abbott delivered steady 6.9% revenue growth anchored by medical devices. Lilly posted explosive 54% revenue growth powered by its GLP-1 obesity and diabetes drugs. Abbott spreads risk across medical devices, diagnostics, nutrition, and branded generics. No single product dominates. The company operates in 160 countries with exposure to cardiovascular, diabetes, and ...